Nadroparin, a blood-thinning drug, halves the risk of developing blood clots in ambulatory cancer patients receiving chemotherapy, and as such could become an important preventive treatment in ...

In the nadroparin arm, subcutaneous nadroparin was administered for 6 weeks (2 weeks at therapeutic dose, and 4 weeks at half therapeutic dose). The patients were eligible to receive additional cycles ...

The low–molecular-weight heparin nadroparin nearly halved the rate of thromboembolic events in ambulatory patients receiving chemotherapy, according to data from the PROTECHT study. However ...

In this multicenter, randomized, open-label study, patients with non–small-cell lung cancer (stage IIIB), hormone-refractory prostate cancer, or locally advanced pancreatic cancer were randomly ...

Nadroparin, a blood-thinning drug, halves the risk of developing blood clots in ambulatory cancer patients receiving chemotherapy, and as such could become an important preventive treatment in ...

Only one randomized trial has compared the efficacy and safety of two different types of LMWH, nadroparin 2,850 U and enoxaparin 40 mg, after colorectal surgery for cancer. [14] Out of 950 ...

Nadroparin (Nadroparin) is a low molecular weight heparin, prescribed for venous thromboembolism, pulmonary embolism and unstable angina. The information provided on this page is intended to serve ...

We then randomly assigned them to receive daily 80 mg of aspirin plus open-label subcutaneous nadroparin (at a dose of 2850 IU, starting as soon as a viable pregnancy was demonstrated), 80 mg of ...

Nadroparin (Cardioparin) is a low molecular weight heparin, prescribed for venous thromboembolism, pulmonary embolism and unstable angina. The information provided on this page is intended to ...

Nadroparin was an effective prophylactic approach towards the reduction in the number of thromboembolic events in patients receiving chemotherapy, according to the results of the placebo ...